Plain-English translation of NCT04870944 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether a new drug called CBL0137 can help children and young adults whose cancers have come back or no longer respond to standard treatments. The medication works by targeting proteins in cancer cells that help them survive and grow. Researchers want to find the right dose and see if this treatment can shrink these hard-to-treat cancers.
Children with recurring or treatment-resistant cancers, especially certain brain tumors, have very few options and poor survival rates. This medication represents a new approach that hasn't been tested in children yet, and this trial could open a door to a different way of fighting these cancers.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an infusion (IV) over 30 minutes on two days each month, with treatment continuing for up to 17 cycles (about 12 months) unless your cancer gets worse or side effects become too severe. Throughout the trial, you'll have regular blood tests, heart function checks (echocardiograms), and scans to monitor how your body is responding. Your doctor will also collect blood samples and may do bone marrow biopsies if needed to understand how the medication is working.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States